Erasca, Inc. Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Erasca, Inc. (ERAS) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $862.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2026-03-12
- Erasca, Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $862.00K, a 35.82% decline from fiscal 2024.
- Erasca, Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2024 was $1.34M, a 5.58% increase from fiscal 2023.
- Erasca, Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2023 was $1.27M, a 17.56% decline from fiscal 2022.
- Erasca, Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2022 was $1.54M, a 84.79% increase from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month |
|---|---|
| 2025-12-31 | $862.00K 10-K · filed 2026-03-12 |
| 2024-12-31 | $1.34M 10-K · filed 2026-03-12 |
| 2023-12-31 | $1.27M 10-K · filed 2025-03-20 |
| 2022-12-31 | $1.54M 10-K · filed 2024-03-27 |
| 2021-12-31 | $835.00K 10-K · filed 2023-03-23 |
| 2020-12-31 | $191.00K 10-K · filed 2022-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |